|
Phio Pharmaceuticals Corp.
Ticker Symbol: PHIO CUSIP: 71880W303 Previous CUSIP: 71880W204 Exchange: NCM
Company's Online Profile
BUSINESS: Phio Pharmaceuticals Corp.. is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA) platform. Therapeutics that use RNA interference have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions.
|
|
Notes: July 2, 2024)-- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-9. The reverse stock split will become effective at 12:01 a.m. Eastern Time on July 5, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on July 5, 2024 under the Company's existing trading symbol, "PHIO." At such time, the Company's common stock will also commence trading with a new CUSIP number, 71880W501. January 14, 2020 -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-55. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 15, 2020 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 15, 2020 under the Company’s existing trading symbol, “PHIO.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 71880W303. _______________ April 18, 2016 -- RXi Pharmaceuticals Corporation (RXII) will effect a one-for-ten (1-10) reverse split of its common stock. The CUSIP number will change to 74979C501.
|
IPO - 1/1/1900
Previous Ticker Symbol: RXII Changed: 11/19/18
Previous Name: RXI Pharmaceuticals Corp. Changed: 11/19/18
Micro Cap Stock -
Market Value $ Million
Click for current PHIO price quote from the NASDAQ
Yahoo News Summary for PHIO
YAHOO! Profile for PHIO
Yahoo Detailed Quote
MarketWatch Quote
MSN Company Report for PHIO
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Address and Phone Numbers |
| Address: 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406 |
| Main Phone Number |
508-929-3640 |
| Fax Number |
Not Available |
| Investor Contact
James Cardia
|
508-929-3634
|
| CEO - Robert Bitterman |
CFO - Robert M. Infarinato |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
